Radiopharmaceutical CMC and import document localization in Latin America: beating the customs decay clock

A delayed customs release is an inconvenience for most investigational products. For a radiopharmaceutical it can be the end of the dose. A shipment of a short half-life isotope that sits in an airport warehouse while an inspector compares the name on the air waybill with the name on the import license is losing activity every hour. If the paperwork does not match, the product can arrive at the site below the activity the protocol requires, and the patient visit is lost. Nothing was wrong with the molecule. Something was wrong with the words.

I'm Julio Martinez-Clark, co-founder of Amavita Sciences™. Before we built a regulatory translation practice, my team at bioaccess® spent years moving investigational products through Latin American ports of entry. This piece is for technical operations directors and logistics leads in radiopharma and advanced therapies: why chemistry, manufacturing and controls (CMC) documentation and import paperwork cannot be treated as routine translation, and how to structure them so that customs, health and radiation authorities all read the same product.

Physical half-life sets the margin. A few reference points that matter to clinical supply planning:

• Gallium-68: about 68 minutes. Fluorine-18: about 110 minutes. These are generally produced close to the point of use.
• Technetium-99m: about 6 hours. Copper-64: about 12.7 hours. Zirconium-89: about 78 hours.
• Lutetium-177: about 6.6 days. Iodine-131: about 8 days. Actinium-225: about 10 days.

For the isotopes in the 6- to 80-hour band, cross-border shipment is realistic, and that is exactly where documentation errors hurt most. Copper-64 loses half its activity every 12.7 hours. A one-day hold at customs is not a scheduling problem. It changes whether the dose can still be given within the protocol's activity window. Longer-lived therapeutic isotopes give more room, but they come with tighter radiation protection and waste requirements, so the documentation burden does not get lighter.

The practical consequence: every document that travels with the shipment or is checked at the border must be correct before the shipment leaves the production site. There is no time to fix a mismatch on arrival.

A radiopharmaceutical for a clinical trial in Latin America is usually examined by three kinds of authority, and each one reads a different subset of your documents.

1. The health regulator. COFEPRIS in Mexico, ANVISA in Brazil, INVIMA in Colombia, DIGEMAPS in the Dominican Republic and their peers authorize the clinical trial and the import of the investigational product. They read the CMC package, the investigator's brochure and the trial authorization.
2. The nuclear or radiation authority. Radioactive material has its own licensing track. In Colombia, the Servicio Geológico Colombiano issues the licencia de importación de material radiactivo under the procedure set by Ministerio de Minas y Energía Resolución 18-1419 de 2004. In Brazil the nuclear authority is CNEN; in Mexico it is CNSNS. These authorities read the radiation safety documentation, the activity, the isotope and the receiving facility's authorization.
3. Customs. Customs reads the commercial and transport documents: the invoice or pro forma, the air waybill, the dangerous goods declaration and the import permits from the other two authorities.

Brazil is a good example of how specific this gets. Under ANVISA RDC 945/2024, Chapter X, the import of investigational products for a clinical trial runs through the Documento para Importação (DI) tied to the clinical development dossier (DDCM). Article 82 says changes to the product information on the DI can only be made by request to ANVISA's clinical research area. Article 83 allows ANVISA to issue the DI before the trial is approved, but the product must stay in a protected area until approval is published. If the product name, strength or presentation on your shipping documents does not match the DI, you are not fixing that at the airport.

Commercial translation workflows treat CMC files and shipping paperwork as separate jobs. The CMC module goes to one translator, the investigator's brochure to another, and the shipping documents are filled in by a logistics coordinator from a template. Each piece can be well translated and the package can still fail, because nobody owned consistency across them.

The failure points we see most often:

• Product name drift. The code name, the INN or proposed name, and the radiolabeled form are written differently across the DI or import license, the CMC module, the label and the air waybill.
• Activity and units. Activity stated in mCi in one document and MBq or GBq in another, with rounding that does not reconcile, or a reference time and time zone missing from the calibration statement.
• Decimal and date formats. A decimal comma in the Spanish or Portuguese document and a decimal point in the English source, or a day-month date read as month-day.
• Isotope and form descriptors. Inconsistent wording for the radionuclide, the chemical form and the physical state between the radiation license and the dangerous goods declaration.
• Manufacturer and site names. The production site named one way on the certificate of analysis and another way in the CMC module.

Each of these looks minor in a translation review. At a port of entry, any of them can be a reason to hold the shipment.

Transport of radioactive material follows the IAEA Regulations for the Safe Transport of Radioactive Material (SSR-6), reflected for air shipments in the IATA Dangerous Goods Regulations, Class 7. The package category, transport index and UN number on the shipping papers have to match the package labels and the radiation license. These are not documents to localize loosely. The terms are defined, and the local-language versions should use the terms the receiving authority uses.

Many radiopharmaceuticals also carry temperature requirements. The temperature excursion procedure belongs in the pharmacy manual, translated with the same discipline as the CMC module: what counts as an excursion, who decides whether the product can be used, and how that decision is documented. If the site pharmacist reads a different threshold in Spanish than the one in the English stability data, you have a deviation waiting to happen.

Investigator site staff also need the local-language version of handling, dose calibration, waste and spill procedures. That material sits outside the regulatory dossier, but it is part of the same terminology set and should come from the same termbase.

Our approach is to treat the shipment's document set as one controlled package, validated before the first shipment and after every change. The steps:

1. Build the product termbase first. Product name and code, radionuclide, chemical form, strength and activity expressions, reference time convention, manufacturer and site names, storage conditions. One approved rendering per language.
2. Map every document to its reader. List which documents each authority, plus customs, will check. Typically the CMC module and the investigator's brochure for the health regulator, radiation safety and facility documents for the nuclear authority, and the invoice, air waybill, dangerous goods declaration and permits for customs.
3. Cross-check identifiers, not just text. Run a reconciliation of every identifier, number, unit and date across the set: permit numbers, lot numbers, activity at calibration, expiry. This is a table exercise, not a prose review.
4. Localize the templates, not each shipment. Shipping documents are filled in under time pressure. Give the logistics team pre-approved bilingual templates with locked terminology so the only fields that change per shipment are lot, activity, time and quantities.
5. Re-validate on change. When the CMC section is amended, the product presentation changes or a new country is added, re-run the reconciliation before the next shipment. Under rules like RDC 945/2024 Article 82, the import document itself may need to be updated through the regulator first.

None of this is exotic. It is the same discipline we apply to device dossiers, with a much shorter tolerance for error.

For a sponsor planning a Latin American radiopharmaceutical study, I recommend three plan lines that are often missing:

• A terminology and document-reconciliation step that finishes before the import application is filed, not after the trial is approved.
• A named owner for the shipment document set, on the sponsor or vendor side, who signs off before each first shipment to a new country.
• A dry run with the customs broker and the receiving site, using the real templates, before the first patient is scheduled.

Amavita Sciences™ localizes CMC modules, investigator's brochures, pharmacy manuals and import documentation as one terminology set across Spanish and Portuguese markets, through our pipeline of localization, medical review and regulatory QA. See our pharmaceutical translation services, or if you want us to review a shipment document set before your first import, start a LATAM pilot. Send the document list and the destination countries, and we will return a reconciliation map before the isotope leaves the production site.

Operator guidance only; not legal advice. Confirm current requirements with each health, radiation and customs authority before shipping.